Opus and Novartis in assay deal

Opus Diagnostics, a wholly-owned subsidiary of Caprius (CAPR), entered into an agreement with Novartis (SWX:NOVN; NVS) to develop and market worldwide an assay to monitor levels of NOVN's Certican eve...